Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Copyright © 2004 Korean Cancer Association
Patient characteristics
*carcinoembryonic antigen.
Objective tumor response rates
*carcinoembryonic antigen
Prognostic factors in univariate analysis
*time to progression, †overall survival.
Toxicities (n=55)
*National Cancer Institute-Common Toxicity Criteria.
*carcinoembryonic antigen.
*carcinoembryonic antigen
*time to progression, †overall survival.
*National Cancer Institute-Common Toxicity Criteria.